Open-label single-arm clinical trial (J Affect Disord 2023; Wu Z, Gan Y, Li N, Lan X, Wang C; single centre, China; PMID 37156269). Participants: n≈122 enrolled adults with DSM-5 MDD or bipolar depression who failed ≥2 antidepressant trials or had suicidal ideation; exclusions: alcohol/drug dependence, recent mania/hypomania, unstable medical findings. All received 6 IV ketamine hydrochloride infusions (0.5 mg/kg over 40 min) on a Mon–Wed–Fri schedule over 2 weeks; concomitant psychotropics permitted but dose-stable. Analytic sample: n=103 completers at baseline and day 13; 19 participants (18.4%) did not complete day 26 follow-up. Primary outcomes: MADRS, SDS (social/occupational/home domains), GAF; pain assessed by SF-MPQ (sensory, affective, present pain intensity indices) at baseline, day 13, day 26. CT.gov: 0 hits; PubMed DataBankList: empty; no registration number in methods.
6 intravenous infusions of ketamine (0.5 mg/kg) over 2 weeks
Administered via intravenous pump with 0.9% sodium chloride injection over 40 min; infusions occurred Monday, Wednesday, and Friday over a two-week period.